Literature DB >> 2890193

Pituitary adenomas of the multiple endocrine neoplasia type I syndrome.

B W Scheithauer1, E R Laws, K Kovacs, E Horvath, R V Randall, J A Carney.   

Abstract

In a series of 1,500 pituitary adenomas surgically resected at Mayo Clinic, 41 (2.7%) occurred in the setting of multiple endocrine neoplasia, type I (MEN-I). Of the 40 patients (18 males, 22 females), 21 (52%) presented with clinical evidence of a pituitary neoplasm, 13 with hyperparathyroidism, and two with functional islet cell tumor. Of the 41 tumors, 11 (27%) were microadenomas, and 30 (73%) were macroadenomas. Immunocytochemical studies demonstrated the following reactivities: GH (4), GH/PRL (6), GH/PRL/glycoprotein (7), GH/ACTH/glycoprotein (1), PRL (16), PRL/TSH (1), ACTH (3), and null cell adenoma (3). We conclude that, in comparison with pituitary adenomas occurring in the general population, those occurring in association with MEN-I are (1) more often endocrinologically functional, (2) more frequently GH- or PRL-producing, and (3) clinicopathologically similar in terms of the subjects age and sex as well as of tumor size and invasiveness.

Entities:  

Mesh:

Year:  1987        PMID: 2890193

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  25 in total

1.  Future avenues in treatment of pituitary adenomas.

Authors:  R Fahlbusch
Journal:  Pituitary       Date:  1999-08       Impact factor: 4.107

2.  Coexisting acromegaly and a unilateral cortisol-producing adrenal adenoma: a possible variant of multiple endocrine neoplasia type I.

Authors:  H Watanobe; K Kudo; T Okushima; M Nakazono; M Kudo; K Takebe
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

3.  The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.

Authors:  C A Stratakis; M A Tichomirowa; S Boikos; M F Azevedo; M Lodish; M Martari; S Verma; A F Daly; M Raygada; M F Keil; J Papademetriou; L Drori-Herishanu; A Horvath; K M Tsang; M Nesterova; S Franklin; J-F Vanbellinghen; V Bours; R Salvatori; A Beckers
Journal:  Clin Genet       Date:  2010-11       Impact factor: 4.438

4.  Sellar meningiomas: an endocrinologic perspective.

Authors:  Matheni Sathananthan; Airani Sathananthan; Bernd W Scheithauer; Caterina Giannini; Fredric B Meyer; John L D Atkinson; Dana Erickson
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

Review 5.  Multiple endocrine neoplasia type I: general features and new insights into etiology.

Authors:  M L Brandi
Journal:  J Endocrinol Invest       Date:  1991-01       Impact factor: 4.256

6.  Multiple intracranial recurrent tumors with hyperprolactinemia combined with a parasellar malignant fibrous histiocytoma long after transfrontal surgery and irradiation to a pituitary adenoma.

Authors:  M Fujikawa; K Okamura; K Sato; M Shiratsuchi; T Yao; T Mizokami; M Fujishima
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

Review 7.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 8.  Familial pituitary tumor syndromes.

Authors:  Marianne S Elston; Kerrie L McDonald; Roderick J Clifton-Bligh; Bruce G Robinson
Journal:  Nat Rev Endocrinol       Date:  2009-06-30       Impact factor: 43.330

9.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways.

Authors:  Paraskevi Xekouki; Monalisa Azevedo; Constantine A Stratakis
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

10.  Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells.

Authors:  Matthew Miller; Shenglin Chen; Jeffrey Woodliff; Sanjay Kansra
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.